News | April 08, 2007

Abiomed Impella 2.5 Recognized for Innovative Design

The Impella 2.5 circulatory support system, by Abiomed Inc. was among 35 innovative healthcare products to receive a 2007 Medical Design Excellence Award — MDEA is the premier awards program for the medical technology community.

The Impella 2.5 is a Ventricular Assist Device designed to pump up to 2.5 liters of blood per minute, supporting the heart in situations when it cannot function on its own. Available in Europe under CE Mark approval and currently in pilot clinical trial studies in the U.S. under an Investigational Device Exemption (IDE), the Impella 2.5 was recognized in the critical-care and emergency medicine products category for its product innovation, design and engineering achievement, end-user benefit, and cost-effectiveness in manufacturing and healthcare delivery.

Presentation of the 2007 MDEA awards will take place on Wednesday, June 13, in a ceremony at the Medical Design & Manufacturing (MD&M) East 2007 Conference and Exposition, in New York City.

For more information visit www.abiomed.com.


Additional Content

News | Ventricular Assist Devices (VAD)

June 19, 2024 — When electrophysiologist Eugenio Cingolani, MD, isn’t seeing patients, he can usually be found in his ...

Home June 19, 2024
Home
News | Ventricular Assist Devices (VAD)

October 31, 2023 — Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop ...

Home October 31, 2023
Home
News | Ventricular Assist Devices (VAD)

June 7, 2023 — Magenta Medical Ltd. has announced the initiation of its FDA-approved Early Feasibility Study with the ...

Home June 07, 2023
Home
News | Ventricular Assist Devices (VAD)

March 1, 2023 — Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, today ...

Home March 01, 2023
Home
News | Ventricular Assist Devices (VAD)

November 2, 2022 — For decades, left ventricular-assist devices (LVADs) have extended the lives of people whose hearts ...

Home November 02, 2022
Home
Subscribe Now